Durvalumab + olaparib + paclitaxel in High-risk HER2-negative ESBC: I-SPY2 trial results
I-SPY2 Trial, Cancer Cell 39, 989–998, 2021 Authors: Pusztai et al.
Read MoreI-SPY2 Trial, Cancer Cell 39, 989–998, 2021 Authors: Pusztai et al.
Read MorePUBLICATION: ASCO 2021 Authors Joyce O’Shaughnessy1, Virginia G. Read More
PUBLICATION: ASCO 2021 Authors Cathy Graham1, Douglas K. Read More
PUBLICATION: ASCO 2021 Authors Nina D’Abreo1,2, Abhinav Rohatgi1,2, Douglas Read More
NSABP B-42 Trial, ASCO 2021 Abstract #502 Authors: Rastogi, et al.
Read MorePublication: St. Gallen Authors: Jennifer A. Crozier, Lisa Blumencranz, Read More
Publication: St. Gallen Authors: E. Göker, M.P. Hendriks, M. van Read More
Publication: St Gallen Authors: M. Kleijn, J. McKelley, Read More
Publication: Miami Breast Authors Pat Whitworth, James Read More
Publication: Miami Breast Authors: Pat Whitworth, Jennifer A. Crozier, Robert Read More